Correction to: Preclinical development of ZED8, an ⁸⁹Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy

Affiliations

• ¹ Department of Biomedical Imaging, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ² Department of Structural Biology, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ³ Department of Cancer Immunology, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁴ Preclinical and Translational Pharmacokinetics, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁵ Research Pathology, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁶ Oncology Exploratory Clinical Development, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁷ BioAnalytical Sciences, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁸ Safety Assessment Pathology, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ⁹ Safety Assessment Toxicology, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
• ¹⁰ Department of Biomedical Imaging, Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA. williams.simon@gene.com.